#healthcare
3 post
FLASHAstraZeneca strikes $1.5 billion AI drug discovery deal with Insitro
AstraZeneca $AZN announced a landmark agreement worth up to $1.5 billion with AI drug discovery platform Insitro to accelerate development of new pharmaceuticals. The partnership aims to leverage a...
FLASHBristol Myers' lung disease and cancer drugs succeed in late-stage trials
Bristol Myers Squibb $BMY announced positive results from Phase 3 trials for two drug candidates targeting lung disease and cancer, boosting investor confidence in its pipeline and lifting the stoc...
FLASHArriVent stock plunges 60% after failed clinical trial, shares crater
ArriVent Biopharma's stock collapsed approximately 60% following the failure of a clinical trial for one of its key therapeutic programs. The dramatic decline reflects the high-risk nature of biote...